2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
04.27.17
Catabasis Pharmaceuticals to Report First Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, May 11
04.25.17
Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
04.18.17
Catabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting
03.16.17
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights
03.15.17
Catabasis Pharmaceuticals to Present at Oppenheimer’s 27th Annual Healthcare Conference
03.13.17
Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference
03.02.17
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Developments on Thursday, March 16
03.01.17
Catabasis Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference
02.17.17
Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
01.31.17
Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
01.19.17
Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology
01.05.17
Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
01.04.17
Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.